ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1028

Knee Osteoarthritis and Mortality: The Osteoarthritic Initiative

Jane Cauley1, Michael Nevitt2, Kai Sun3, Jason Maeda3, C. Kent Kwoh4, Leena Sharma5, Rebecca Jackson6, Susan Rubin3 and Marc Hochberg7, 1University of Pittsburgh Graduate School of Public Health, Pittsbugh, PA, 2University of California San Francisco, Orinda, CA, 3University of California San Francisco, San Francisco, CA, 4University of Arizona College of Medicine, Tuscon, AZ, 5Northwestern University, Chicago, IL, 6Ohio State University, Columbus, OH, 7University of Maryland School of Medicine, Baltimore, MD

Meeting: ACR Convergence 2021

Keywords: Mortality, OAI, Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: A recent international individual participant data (IPD) meta-analysis (n=10,723) reported a 35-37% increased mortality risk among individuals with painful knees (no radiographic OA) and symptomatic radiographic knee OA (Leyland K et al 2021). We examined whether these results could be replicated in the Osteoarthritis (OAI) cohort (not included in the international IPD) using complete, long-term data on participant deaths from the OAI.

Methods: The OAI is a prospective cohort study investigating risk factors and biomarkers associated with the development and progression of knee OA. A total 4,796 adults age 45-79 years with or at high risk of developing knee OA were recruited at five US clinical sites. A National Death Index search was initiated to identify all deaths from 2004-2018. We used OAI baseline data on radiographic knee OA (K-L grade >=2), knee symptoms (pain on most days of a month in past year) and symptomatic OA (radiographic OA and symptoms in the same knee) to classify participants into four groups: symptomatic OA in one or both knees; no symptomatic OA but has radiographic OA in one or both knees; no radiographic OA but has symptoms in one or both knees; no radiographic OA or symptoms in either knee (referent group). Cox proportional hazards models were used to calculate hazard ratios (HR) for mortality, and their 95% confidence Intervals (CI), adjusted for covariates, in each group compared to the referent group. We excluded those who had a knee replacement at baseline (n=63) and missing data on covariates.

Results: The mean age of the cohort at baseline was 61 years; 80% were white; 58% were women. Over an average follow-up of 9.2 years, 515 (11.3%) died. Of those with no radiographic OA and no symptoms, 9.7% died; no radiographic OA with symptoms, 8.2% died; radiographic OA and no symptoms, 13.4% died and radiographic OA and symptoms, 12.5% died, p< 0.0005, See Table. In multivariable adjusted models there was a marginally significant 28% increase in mortality (p=0.065) in participants with symptomatic knee OA at baseline. The association with mortality was stronger in those with symptomatic knee OA with a K-L grade 3 or 4 HR= 1.32 (1.00, 1.73) compared with those symptomatic OA with K-L score of 2, HR=1.17(0.85, 1.63). We also examined the association between frequent knee symptoms in either knee, adjusting for K-L grade; those with frequent knee pain had an increased risk of death, HR= 1.19 (0.99, 1.43).

Conclusion: These results with complete long-term follow-up data from the OAI cohort are consistent with those from the individual level meta-analysis showing increased mortality among those with symptomatic knee OA.


Disclosures: J. Cauley, None; M. Nevitt, None; K. Sun, None; J. Maeda, None; C. Kwoh, Lilly, 5, Abbvie, 5, Kolon Tissue Gene, 12, DSMB, Regeneron, 1, LG Chem, 1; L. Sharma, None; R. Jackson, None; S. Rubin, None; M. Hochberg, BriOri Biotech, 1, 2.

To cite this abstract in AMA style:

Cauley J, Nevitt M, Sun K, Maeda J, Kwoh C, Sharma L, Jackson R, Rubin S, Hochberg M. Knee Osteoarthritis and Mortality: The Osteoarthritic Initiative [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/knee-osteoarthritis-and-mortality-the-osteoarthritic-initiative/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/knee-osteoarthritis-and-mortality-the-osteoarthritic-initiative/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology